Fifth US Biosimilar To Herceptin Launched By Merck
Ontruzant Biosimilar Available For All Eligible Indications
Merck & Co has launched Ontruzant, the trastuzumab biosimilar developed and manufactured by Samsung Bioepis, in the US following a staggered approval process and earlier intellectual-property hurdles. The list price discount offered by the firm puts it in the middle of the pack among the four other biosimilar players currently on the market.
You may also be interested in...
Roche was forced to revise its forecasts for biosimilar competition last year, but even an upward revision of CHF1bn fell short as biosimilar sponsors stole a march in the US at a level that caught the originator by surprise.
With several biologic molecules opened up to true multi-source competition over the course of 2020, the US biosimilars landscape now looks very different from the start of the year.
Four years after initiating its comparative trastuzumab study, Samsung Bioepis has presented positive data that the firm hopes will help build confidence in the use of biosimilars for prescribers and patients. Meanwhile, the company also has good news for its SB11 ranibizumab biosimilar.